New research shows that young breast cancer patients with high-risk genes may be able to prevent their cancer from returning ...

It's a decision no woman wants to have to make, but new research shows that young breast cancer patients with high-ris ...

RISK-REDUCING surgeries, including bilateral mastectomy (RRM) and salpingo-oophorectomy (RRSO), are associated with improved ...

PanCAN answers questions that came in during our World Pancreatic Cancer Day event about pancreatic cancer early detection.

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast, according to 6-year data from the OlympiA trial.

Women who underwent bilateral mastectomy or removal of ovaries and Fallopian tubes had lower rates of recurrence, ovarian ...

"In BRCA carriers with prior diagnosis of breast cancer ... the specific [risks associated with the] BRCA1 gene," Lambertini ...

Adjuvant Lynparza remains beneficial for patients with BRCA1/2 mutation–positive, HER2-negative high-risk breast cancer, study results have shown.

Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative ...

AstraZeneca (AZN) and Merck (MRK) reported positive long-term survival data for their drug Lynparza in the treatment of ...

One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast ...

Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing ...